Lotte Rasmussen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lotte Rasmussen has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Anton Pottegård
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
28 shared publications - Rikke Wesselhoeft
Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark
9 shared publications - Peter Bjødstrup Jensen
University of Southern Denmark
7 shared publications - Jesper Hallas
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
6 shared publications - Martin Thomsen Ernst
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark
6 shared publications - Mette Bliddal
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark
6 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (9) , e70443
A Catalogue of Dispensation Lengths for Building Treatment Episodes—Application of the Waiting Time Distribution to All Commonly Prescribed Drugs in Denmark
Background: In pharmacoepidemiologic research, correct assignment of the length of single dispensation is critical to build treatment episodes. The parametric reverse waiting time distribution (rWTD) is a particularly attractive data‐driven method to estimate dispensation lengths. Aim: To provide an easily accessible resource of estimated dispensation lengths covering all commonly used drugs for use in treatment episode building in applied pharmacoepidemiologic research. Methods: We used a random 20% sample of the Danish population alive after 1st January 2000 and identified all their prescriptions filled between 2010 and 2022. We applied the rWTD with five random index dates for each individual to estimate parameters that allow calculation of dispensation length estimates. Parameters were estimated with and without age, sex, and dispensed amount as covariates. Results: We present estimated dispensation lengths for the 20 most prescribed drugs and drug classes in Denmark. Estimated dispensation lengths for all drugs are provided online, and in a spreadsheet. The most prescribed drug was paracetamol with an estimated dispensation length of 194 days, while atorvastatin was the most commonly used drug indicated for long‐term use with an estimated dispensation length of 165 days. The dispensation lengths for drugs varied according to age, dispensed volume, sex, and over time. Conclusions: This is a comprehensive overview of dispensation lengths for all commonly prescribed drugs registered in the Danish National Prescription Registry. Data presented in an online resource can be utilized and modified by other researchers providing optimal conditions for high quality pharmacoepidemiologic research.
- 21 August 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (9) , e70443
Open AccessA Catalogue of Dispensation Lengths for Building Treatment Episodes—Application of the Waiting Time Distribution to All Commonly Prescribed Drugs in Denmark
Background: In pharmacoepidemiologic research, correct assignment of the length of single dispensation is critical to build treatment episodes. The parametric reverse waiting time distribution (rWTD) is a particularly attractive data‐driven method to estimate dispensation lengths. Aim: To provide an easily accessible resource of estimated dispensation lengths covering all commonly used drugs for use in treatment episode building in applied pharmacoepidemiologic research. Methods: We used a random 20% sample of the Danish population alive after 1st January 2000 and identified all their prescriptions filled between 2010 and 2022. We applied the rWTD with five random index dates for each individual to estimate parameters that allow calculation of dispensation length estimates. Parameters were estimated with and without age, sex, and dispensed amount as covariates. Results: We present estimated dispensation lengths for the 20 most prescribed drugs and drug classes in Denmark. Estimated dispensation lengths for all drugs are provided online, and in a spreadsheet. The most prescribed drug was paracetamol with an estimated dispensation length of 194 days, while atorvastatin was the most commonly used drug indicated for long‐term use with an estimated dispensation length of 165 days. The dispensation lengths for drugs varied according to age, dispensed volume, sex, and over time. Conclusions: This is a comprehensive overview of dispensation lengths for all commonly prescribed drugs registered in the Danish National Prescription Registry. Data presented in an online resource can be utilized and modified by other researchers providing optimal conditions for high quality pharmacoepidemiologic research.
- Open Access
- 30 July 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (8) , e70423
DU ‐Vigilance; Capturing Unsuspected Problems in Drug Utilization
Key Points: Pharmacovigilance should expand beyond adverse drug reactions. A concept, Drug Utilization Vigilance (DU‐vigilance), is proposed as an approach to detect unsuspected prescribing or utilization problems. DU‐vigilance relies on analyses of large‐scale real‐world data. Aberrant drug utilization is dynamic and requires continuous surveillance. Integrating DU‐vigilance within traditional pharmacovigilance could improve healthcare quality.
- 30 July 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (8) , e70423
Open AccessDU ‐Vigilance; Capturing Unsuspected Problems in Drug Utilization
Key Points: Pharmacovigilance should expand beyond adverse drug reactions. A concept, Drug Utilization Vigilance (DU‐vigilance), is proposed as an approach to detect unsuspected prescribing or utilization problems. DU‐vigilance relies on analyses of large‐scale real‐world data. Aberrant drug utilization is dynamic and requires continuous surveillance. Integrating DU‐vigilance within traditional pharmacovigilance could improve healthcare quality.
- Open Access
- 12 June 2026
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (11) , 957-971
Prescribing quality indicators applicable to register data: A scoping review
- 12 June 2026
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (11) , 957-971
Open AccessPrescribing quality indicators applicable to register data: A scoping review
- Open Access
- 21 April 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 154 (3) , 203-211
Use of Attention Deficit Hyperactivity Disorder Medication Among Danish Children and Adolescents From 2010 to 2023
Introduction: Pharmacological treatment is an important component in the multimodal management of attention deficit hyperactivity disorder (ADHD), but contemporary trends in ADHD medication use among boys and girls in Denmark have not been fully characterized. This study aimed to provide an updated and detailed description of ADHD medication use among Danish children and adolescents during 2010–2023. Methods: We analyzed filled prescriptions for ADHD medication in youths aged 5–17 years in Denmark (2010–2023), calculating incidence rates, prevalence proportions, male/female ratios, treatment persistence, age at initiation, and prescriber setting. Analyses were stratified by sex and age. Results: The incidence rates of ADHD medication use followed a u‐shaped pattern for boys, declining from 0.59 per 100 person‐years in 2010 to 0.34 in 2014, before rising to 1.0 in 2023. Among girls, incidence rates increased continuously from 0.20 per 100 person‐years in 2010 to 0.67 per 100 person‐years in 2023. Prevalence proportions were stable until 2018, where an increase was observed for both sexes, reaching 3.4% for boys and 1.8% for girls in 2023. The male/female incidence and prevalence ratios decreased consistently from 2010 to 2023. ADHD medication was initiated at a median age of 13 years for girls and 11 years for boys. The share of index prescriptions from child and adolescent psychiatry increased, reaching 87% in 2023. Most 5–9‐year‐olds (65%) and almost half of 10–13‐year‐olds (45%) were covered by an ADHD medication prescription 5 years after treatment initiation, as opposed to 29% of 14–17‐year‐olds. Conclusion: ADHD medication use in Denmark increased from 2010 to 2023, particularly among girls, where the prevalence tripled compared to a 1.5‐fold increase in boys. This likely reflects greater awareness of ADHD in girls, although their 2‐year treatment delay compared to boys warrants clinical attention.
- 21 April 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 154 (3) , 203-211
Open AccessUse of Attention Deficit Hyperactivity Disorder Medication Among Danish Children and Adolescents From 2010 to 2023
Introduction: Pharmacological treatment is an important component in the multimodal management of attention deficit hyperactivity disorder (ADHD), but contemporary trends in ADHD medication use among boys and girls in Denmark have not been fully characterized. This study aimed to provide an updated and detailed description of ADHD medication use among Danish children and adolescents during 2010–2023. Methods: We analyzed filled prescriptions for ADHD medication in youths aged 5–17 years in Denmark (2010–2023), calculating incidence rates, prevalence proportions, male/female ratios, treatment persistence, age at initiation, and prescriber setting. Analyses were stratified by sex and age. Results: The incidence rates of ADHD medication use followed a u‐shaped pattern for boys, declining from 0.59 per 100 person‐years in 2010 to 0.34 in 2014, before rising to 1.0 in 2023. Among girls, incidence rates increased continuously from 0.20 per 100 person‐years in 2010 to 0.67 per 100 person‐years in 2023. Prevalence proportions were stable until 2018, where an increase was observed for both sexes, reaching 3.4% for boys and 1.8% for girls in 2023. The male/female incidence and prevalence ratios decreased consistently from 2010 to 2023. ADHD medication was initiated at a median age of 13 years for girls and 11 years for boys. The share of index prescriptions from child and adolescent psychiatry increased, reaching 87% in 2023. Most 5–9‐year‐olds (65%) and almost half of 10–13‐year‐olds (45%) were covered by an ADHD medication prescription 5 years after treatment initiation, as opposed to 29% of 14–17‐year‐olds. Conclusion: ADHD medication use in Denmark increased from 2010 to 2023, particularly among girls, where the prevalence tripled compared to a 1.5‐fold increase in boys. This likely reflects greater awareness of ADHD in girls, although their 2‐year treatment delay compared to boys warrants clinical attention.
- Open Access
- 16 April 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (4)
Patient Characteristics and Risk of Fall‐Related Injuries Among New Users of Opioids in Denmark: A Longitudinal Descriptive Study
Purpose: To assess the 1‐year risk of fall‐related injuries among new users of opioids in Denmark. Methods: Using Danish health registers, we identified all new adult users of opioids between 2010 and 2022 (first time use within 5 years). We performed logistic regression and applied marginal comparisons to estimate risk ratios (RRs) associating baseline risk factors to any fall‐related injury and fall‐related fractures specifically. Patients were followed after opioid initiation until fall‐related injury, death, leaving the country, or 1‐year follow‐up, whichever occurred first. Results: We identified 1 638 358 unique new users of opioids (54% women; median age 58 years). The 1‐year risk of fall‐related injuries and fall‐related fractures was 8.6% and 3.6%, respectively. The risk of fall‐related injuries was highest during the first weeks following opioid initiation. Increasing age, depression, Parkinson's disease, osteoporosis, and prior fall‐related injuries were all associated with new fall‐related injuries in the multivariable analysis. Prior fall‐related injuries was a predictor of new fall‐related injuries (RR 2.15; 95% CI: 2.12–2.18) and fall‐related fractures (RR 1.35; 95% CI: 1.31–1.40). Prior fall‐related fractures was a predictor of new fall‐related injuries (RR 1.96; 95% CI: 1.93–1.99) and fall‐related fractures (RR 6.47; 95% CI: 6.29–6.65). Conclusion: The 1‐year risk for any fall‐related injuries and fractures was 8.6% and 3.6%, respectively, and highest in the first weeks following opioid initiation. Several important risk factors associated with new fall‐related injuries were identified. Physicians should be aware of patient characteristics related to fall risk when prescribing opioids.
- 16 April 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (4)
Open AccessPatient Characteristics and Risk of Fall‐Related Injuries Among New Users of Opioids in Denmark: A Longitudinal Descriptive Study
Purpose: To assess the 1‐year risk of fall‐related injuries among new users of opioids in Denmark. Methods: Using Danish health registers, we identified all new adult users of opioids between 2010 and 2022 (first time use within 5 years). We performed logistic regression and applied marginal comparisons to estimate risk ratios (RRs) associating baseline risk factors to any fall‐related injury and fall‐related fractures specifically. Patients were followed after opioid initiation until fall‐related injury, death, leaving the country, or 1‐year follow‐up, whichever occurred first. Results: We identified 1 638 358 unique new users of opioids (54% women; median age 58 years). The 1‐year risk of fall‐related injuries and fall‐related fractures was 8.6% and 3.6%, respectively. The risk of fall‐related injuries was highest during the first weeks following opioid initiation. Increasing age, depression, Parkinson's disease, osteoporosis, and prior fall‐related injuries were all associated with new fall‐related injuries in the multivariable analysis. Prior fall‐related injuries was a predictor of new fall‐related injuries (RR 2.15; 95% CI: 2.12–2.18) and fall‐related fractures (RR 1.35; 95% CI: 1.31–1.40). Prior fall‐related fractures was a predictor of new fall‐related injuries (RR 1.96; 95% CI: 1.93–1.99) and fall‐related fractures (RR 6.47; 95% CI: 6.29–6.65). Conclusion: The 1‐year risk for any fall‐related injuries and fractures was 8.6% and 3.6%, respectively, and highest in the first weeks following opioid initiation. Several important risk factors associated with new fall‐related injuries were identified. Physicians should be aware of patient characteristics related to fall risk when prescribing opioids.
- 26 November 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (4) , 1156-1166
Geographical variation in the use of glucose‐lowering drugs in type‐2 diabetes in Denmark: A nationwide drug utilization study
Aims: To analyse geographical variation in use of glucose‐lowering drugs (GLDs) for type‐2 diabetes (T2DM) in Denmark. Methods: We included all adults who filled a prescription for a non‐insulin GLD indicated for T2DM from 2010 to 2023 in Denmark. Stratified by each of the five regions, we calculated the annual incidence rate, the annual prevalence proportion and the total volume of dispensed GLDs from 2010 to 2023. We calculated the proportion of incident prescriptions for GLDs that were issued by different prescriber types and characterized non‐insulin GLD users in each region in 2023. Finally, we analysed variation at the municipal level. Results: Totally, data from 478 118 adults were included. The user characteristics were comparable across the regions with no differences in the median age (range 66–67 years) or in the sex distribution (range 56–58% males). In all regions, general practitioners were the main prescribers of GLDs. There were minor regional differences in the use of GLDs, with a predominant and increasing use of metformin, accelerating use of SGLT‐2is and GLP‐1RAs, and declining use of SUs over time. In Q4 2023 the ranges of prevalence per 1000 inhabitants were 31 to 44 for metformin, 16 to 23 for SGLT2is, 14 to 23 for GLP‐1RAs and 1.37 to 1.58 for SUs. There were some differences in characteristics of GLD users across regions, with a slightly higher prevalence of diabetes‐related complications and larger involvement of hospital physicians in the Capital Region compared to the other regions. We identified four municipality clusters that differed marginally in the prescribing pattern of non‐insulin GLD. Conclusion: The minor differences in the use of GLDs indicate equal access to GLDs across Denmark. Differences at the municipal level call for future studies to investigate if these reflect differences in clinical practice or differences in T2DM populations.
- 26 November 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (4) , 1156-1166
Geographical variation in the use of glucose‐lowering drugs in type‐2 diabetes in Denmark: A nationwide drug utilization study
Aims: To analyse geographical variation in use of glucose‐lowering drugs (GLDs) for type‐2 diabetes (T2DM) in Denmark. Methods: We included all adults who filled a prescription for a non‐insulin GLD indicated for T2DM from 2010 to 2023 in Denmark. Stratified by each of the five regions, we calculated the annual incidence rate, the annual prevalence proportion and the total volume of dispensed GLDs from 2010 to 2023. We calculated the proportion of incident prescriptions for GLDs that were issued by different prescriber types and characterized non‐insulin GLD users in each region in 2023. Finally, we analysed variation at the municipal level. Results: Totally, data from 478 118 adults were included. The user characteristics were comparable across the regions with no differences in the median age (range 66–67 years) or in the sex distribution (range 56–58% males). In all regions, general practitioners were the main prescribers of GLDs. There were minor regional differences in the use of GLDs, with a predominant and increasing use of metformin, accelerating use of SGLT‐2is and GLP‐1RAs, and declining use of SUs over time. In Q4 2023 the ranges of prevalence per 1000 inhabitants were 31 to 44 for metformin, 16 to 23 for SGLT2is, 14 to 23 for GLP‐1RAs and 1.37 to 1.58 for SUs. There were some differences in characteristics of GLD users across regions, with a slightly higher prevalence of diabetes‐related complications and larger involvement of hospital physicians in the Capital Region compared to the other regions. We identified four municipality clusters that differed marginally in the prescribing pattern of non‐insulin GLD. Conclusion: The minor differences in the use of GLDs indicate equal access to GLDs across Denmark. Differences at the municipal level call for future studies to investigate if these reflect differences in clinical practice or differences in T2DM populations.
- Open Access
- 21 November 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e354
The overlooked link between reproductive system disorders and depression: a cohort study in 2 million women
Background: Depression rates are higher in women, especially during periods of hormonal fluctuation. Reproductive system disorders (RSDs), which often disrupt hormonal balance, may contribute to this mental health burden. Despite their prevalence and significant health implications, the link between RSDs and depression remains underexplored, leaving a gap in understanding these women’s mental health risks. Methods: Using Danish nationwide health registers (2005–2018), we conducted a cohort study of 2,295,824 women aged 15–49, examining depression outcomes in 265,891 women diagnosed with 24 RSDs, including endometriosis, polycystic ovary syndrome, and pain-related diagnoses. For each RSD, age-matched controls were selected. We calculated incidence rates, incidence rate ratios, and prevalence proportions of depression diagnoses or antidepressant use around RSD diagnosis. Results: Across all RSD subtypes, women demonstrated higher rates of depression both before and after diagnosis, with a peak within the year following diagnosis. Incidence rate ratios within 1 year of RSD diagnosis ranged from 1.15 (95% confidence interval [CI] 1.06–1.25) to 2.09 (95% CI 1.98–2.21), depending on RSD subtype. Elevated depression prevalence was observed 3 years before diagnosis, suggesting mental health impacts may have preceded clinical RSD identification. Conclusions: This study reveals a striking association between RSDs and depression. Women with RSDs are more likely to suffer from depression, before and after RSD diagnosis, highlighting the need for integrated mental health screening and intervention. With over 10% of women affected by RSDs, addressing this overlooked mental health burden is imperative for improving well-being in a significant portion of the population.
- 21 November 2025
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 55, e354
Open AccessThe overlooked link between reproductive system disorders and depression: a cohort study in 2 million women
Background: Depression rates are higher in women, especially during periods of hormonal fluctuation. Reproductive system disorders (RSDs), which often disrupt hormonal balance, may contribute to this mental health burden. Despite their prevalence and significant health implications, the link between RSDs and depression remains underexplored, leaving a gap in understanding these women’s mental health risks. Methods: Using Danish nationwide health registers (2005–2018), we conducted a cohort study of 2,295,824 women aged 15–49, examining depression outcomes in 265,891 women diagnosed with 24 RSDs, including endometriosis, polycystic ovary syndrome, and pain-related diagnoses. For each RSD, age-matched controls were selected. We calculated incidence rates, incidence rate ratios, and prevalence proportions of depression diagnoses or antidepressant use around RSD diagnosis. Results: Across all RSD subtypes, women demonstrated higher rates of depression both before and after diagnosis, with a peak within the year following diagnosis. Incidence rate ratios within 1 year of RSD diagnosis ranged from 1.15 (95% confidence interval [CI] 1.06–1.25) to 2.09 (95% CI 1.98–2.21), depending on RSD subtype. Elevated depression prevalence was observed 3 years before diagnosis, suggesting mental health impacts may have preceded clinical RSD identification. Conclusions: This study reveals a striking association between RSDs and depression. Women with RSDs are more likely to suffer from depression, before and after RSD diagnosis, highlighting the need for integrated mental health screening and intervention. With over 10% of women affected by RSDs, addressing this overlooked mental health burden is imperative for improving well-being in a significant portion of the population.
- Open Access
- 5 November 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (11) , e70256
Age‐ and Sex‐Related Trends in Psychotropic Prescribing Among Youths in Denmark and the United States : 2010–2020
Objectives: To compare age‐ and sex‐specific trends of psychotropic prescribing between Danish and US 3–17‐year‐old youths. Methods: A consecutive annual cross‐sectional study of trends in psychotropic prescribing from 2010 to 2020. Data sources included the Danish National Prescription Registry data and, for the US, a 25% random sample of the IQVIA PharMetrics Plus for Academics database. Psychotropic prescribing (i.e., ADHD medications, antidepressants, and antipsychotics), measured as annual prevalence, was estimated for each therapeutic class, by age group and sex, separately by country. We used Joinpoint models to calculate the average annual percentage change (AAPC). Results: ADHD medication prescribing decreased for 5–9 year‐olds in both countries from 2010 to 2020, while prescribing among 10–17 year‐olds was stable in the US and increased in Denmark, particularly among females (AAPC = 4.2% versus 1.4% among males). Antidepressant prescribing increased in older US youths, especially among 14–17 year‐olds (AAPC = 6.5%), and females (AAPC = 7.2%). In Denmark, however, prescribing was low and decreased over time, especially among females (AAPC = −4.2%). Antipsychotic prescribing decreased in both countries for all age groups, with the largest decrease among males (Denmark: AAPC = −5.2% and US: AAPC = −6.1%). Conclusion: Pediatric antipsychotic prescribing generally decreased, whereas ADHD medication and antidepressant prescribing presented opposing patterns in the two countries. ADHD medication prescribing increased among Danish females and adolescents, but was stable in the US. Antidepressant prescribing decreased in Denmark, particularly among females, which opposed the marked rise for this group in the US. Future cross‐national studies should examine the rationale underpinning variation in antidepressant prescribing.
- 5 November 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (11) , e70256
Open AccessAge‐ and Sex‐Related Trends in Psychotropic Prescribing Among Youths in Denmark and the United States : 2010–2020
Objectives: To compare age‐ and sex‐specific trends of psychotropic prescribing between Danish and US 3–17‐year‐old youths. Methods: A consecutive annual cross‐sectional study of trends in psychotropic prescribing from 2010 to 2020. Data sources included the Danish National Prescription Registry data and, for the US, a 25% random sample of the IQVIA PharMetrics Plus for Academics database. Psychotropic prescribing (i.e., ADHD medications, antidepressants, and antipsychotics), measured as annual prevalence, was estimated for each therapeutic class, by age group and sex, separately by country. We used Joinpoint models to calculate the average annual percentage change (AAPC). Results: ADHD medication prescribing decreased for 5–9 year‐olds in both countries from 2010 to 2020, while prescribing among 10–17 year‐olds was stable in the US and increased in Denmark, particularly among females (AAPC = 4.2% versus 1.4% among males). Antidepressant prescribing increased in older US youths, especially among 14–17 year‐olds (AAPC = 6.5%), and females (AAPC = 7.2%). In Denmark, however, prescribing was low and decreased over time, especially among females (AAPC = −4.2%). Antipsychotic prescribing decreased in both countries for all age groups, with the largest decrease among males (Denmark: AAPC = −5.2% and US: AAPC = −6.1%). Conclusion: Pediatric antipsychotic prescribing generally decreased, whereas ADHD medication and antidepressant prescribing presented opposing patterns in the two countries. ADHD medication prescribing increased among Danish females and adolescents, but was stable in the US. Antidepressant prescribing decreased in Denmark, particularly among females, which opposed the marked rise for this group in the US. Future cross‐national studies should examine the rationale underpinning variation in antidepressant prescribing.
- Open Access
- 3 September 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (4) , e70094
Tools for Evaluating Potentially Inappropriate Medication Use in Older Adults: A Scoping Review Assessing Suitability for Register‐Based Research
This scoping review provides an overview of tools used to assess potentially inappropriate prescribing among older adults and discusses their suitability for register‐based research. We performed a systematic search using PubMed (March 2024), retrieving 5493 records. Studies were included if they evaluated potentially inappropriate medication use among older adults with a mean or median age of ≥ 65 years. Identified tools were described by characteristics, usage frequency, and applicability to register‐based research by identifying required data types. A total of 419 studies were included, using 44 different tools, including multiple versions. Beers criteria and the Screening Tool of Older People's Prescriptions were most often used (50% and 19%, respectively). Ten tools were used in five or more studies, each differing in structure, particularly regarding the clinical information required. The European list of potentially inappropriate medications, the PRISCUS list, the Zhan criteria, and the Norwegian General Practice criteria do not require clinical data on medical history, symptoms, laboratory tests or other parameters, making them particularly useful for register‐based research. Specific segments of other tools can also be applied effectively. To generate valid and meaningful results, the availability of required data is a crucial consideration for researchers when selecting the most appropriate tool.
- 3 September 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (4) , e70094
Open AccessTools for Evaluating Potentially Inappropriate Medication Use in Older Adults: A Scoping Review Assessing Suitability for Register‐Based Research
This scoping review provides an overview of tools used to assess potentially inappropriate prescribing among older adults and discusses their suitability for register‐based research. We performed a systematic search using PubMed (March 2024), retrieving 5493 records. Studies were included if they evaluated potentially inappropriate medication use among older adults with a mean or median age of ≥ 65 years. Identified tools were described by characteristics, usage frequency, and applicability to register‐based research by identifying required data types. A total of 419 studies were included, using 44 different tools, including multiple versions. Beers criteria and the Screening Tool of Older People's Prescriptions were most often used (50% and 19%, respectively). Ten tools were used in five or more studies, each differing in structure, particularly regarding the clinical information required. The European list of potentially inappropriate medications, the PRISCUS list, the Zhan criteria, and the Norwegian General Practice criteria do not require clinical data on medical history, symptoms, laboratory tests or other parameters, making them particularly useful for register‐based research. Specific segments of other tools can also be applied effectively. To generate valid and meaningful results, the availability of required data is a crucial consideration for researchers when selecting the most appropriate tool.
- Open Access
- 7 July 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (2) , e70076
Use of Potentially Inappropriate Medications Identified by STOPPFrail Among Danish Care Home Residents: A Nationwide Drug Utilisation Study
Care home residents represent a frail population with limited life expectancy and are often prescribed multiple medications. As therapeutic goals shift in this population, certain treatments may become inappropriate. This study aims to describe potentially inappropriate medication use among Danish care home residents using the Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) in a nationwide cohort of all Danish care home residents admitted 2015–2023, focusing on the time around admission and the last year of life. The cohort comprised 129 635 residents (61% women, median age 84 years). Around admission, 88% used at least one STOPPFrail medication, most commonly antihypertensives (58% before, 55% after), lipid‐lowering therapies (31%, 27%) and proton‐pump inhibitors (30%, 30%). The rate of new use increased from 2.6/100 residents/month 2 years before admission, peaking at 9.6/100 residents/month 2 months prior. Hospital physician prescribing increased as care home admission approached, after which general practitioners prescribed most prescriptions. Over 90% used at least one STOPPFrail medication during the last year of life, with increases in proton‐pump inhibitors and antipsychotics, the latter most frequently initiated in the last 4 months. These findings underscore the importance of regular assessment and targeted efforts to improve prescribing appropriateness.
- 7 July 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (2) , e70076
Open AccessUse of Potentially Inappropriate Medications Identified by STOPPFrail Among Danish Care Home Residents: A Nationwide Drug Utilisation Study
Care home residents represent a frail population with limited life expectancy and are often prescribed multiple medications. As therapeutic goals shift in this population, certain treatments may become inappropriate. This study aims to describe potentially inappropriate medication use among Danish care home residents using the Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) in a nationwide cohort of all Danish care home residents admitted 2015–2023, focusing on the time around admission and the last year of life. The cohort comprised 129 635 residents (61% women, median age 84 years). Around admission, 88% used at least one STOPPFrail medication, most commonly antihypertensives (58% before, 55% after), lipid‐lowering therapies (31%, 27%) and proton‐pump inhibitors (30%, 30%). The rate of new use increased from 2.6/100 residents/month 2 years before admission, peaking at 9.6/100 residents/month 2 months prior. Hospital physician prescribing increased as care home admission approached, after which general practitioners prescribed most prescriptions. Over 90% used at least one STOPPFrail medication during the last year of life, with increases in proton‐pump inhibitors and antipsychotics, the latter most frequently initiated in the last 4 months. These findings underscore the importance of regular assessment and targeted efforts to improve prescribing appropriateness.